PTX 102
Alternative Names: PTX-102Latest Information Update: 13 Feb 2024
At a glance
- Originator Providence Therapeutics
- Class Antineoplastics; Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Jan 2024 Preclinical trials in Solid tumours in Canada (unspecified route) before January 2024 (Providence Therapeutics pipeline, January 2024)